胰腺导管腺癌患者切除与探查比率及相关结局
该研究纳入2018至2020年因胰腺导管腺癌接受手术探查的681例患者,计算切除与探查比率(RER),分析未完成切除的原因及生存结局。总体RER为89.7%,直接手术组为90.5%,新辅助治疗后组为89.1%;新辅助治疗后组中RER从可切除病的96.1%降至交界可切除病的86.6%和局部晚期病的61.9%。未完成切除者中位生存约1年。
要点
- 总体切除与探查比率为89.7%,直接手术组90.5%,新辅助治疗后组89.1%。
- 新辅助治疗后组RER:可切除病96.1%,交界可切除病86.6%,局部晚期病61.9%。
- 未完成切除的中位生存约1年;直接手术切除后中位生存36.9个月,新辅助治疗后切除29.5个月。
核心结论
- 该分析提供了在有经验机构选择手术探查的全部胰腺导管腺癌患者中关于切除率、术中未完成切除原因及生存结局的当代信息。
研究设计与样本
- 研究纳入2018年至2020年因胰腺导管腺癌接受手术探查的患者681例,计算切除与探查比率(RER),并使用多因素模型识别与未完成切除及生存相关的因素。
主要发现
- 直接手术探查296例(43.7%),新辅助治疗后探查385例(56.3%)。
- 总体RER为89.7%,直接手术组为90.5%,新辅助治疗后组为89.1%。
- 新辅助治疗后组中,RER从可切除病的96.1%降至交界可切除病的86.6%和局部晚期病的61.9%。
- 未完成切除的主要原因在 presumed 可切除/交界可切除病中为隐匿性转移(直接手术与新辅助治疗后手术之间无差异),在局部晚期病中为局部不可切除。
- 未完成切除的中位生存约1年;直接手术组胰腺切除后中位生存36.9个月,新辅助治疗后组为29.5个月,新辅助治疗后切除患者自诊断起中位生存34.5个月。
关键数值与推荐
- 直接手术探查中无术前变量与未完成切除相关,而新辅助治疗后解剖分期与手术未完成的可能性相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate resection/exploration ratios (RERs), reasons for omission of pancreatectomy, and survival outcomes in patients undergoing surgical exploration with resection intent for pancreatic ductal adenocarcinoma (PDAC). BACKGROUND: While surgical indications for PDAC are expanding, information about intraoperative attrition is lacking. METHODS: The RER was calculated in patients with PDAC undergoing exploration from 2018 through 2020. Factors associated with uncompleted resection and survival were identified using multivariable models. RESULTS: In total, 681 patients were included. Upfront explorations were 296 (43.7%), and postneoadjuvant explorations were 385 (56.3%). The overall RER was 89.7% (90.5% in the upfront setting and 89.1% postneoadjuvant treatment). In this latter subgroup, the RER decreased from 96.1% in resectable disease to 86.6% in borderline resectable disease and 61.9% in locally advanced disease. The primary reasons for uncompleted resection were occult metastases in presumed resectable/borderline resectable disease (without difference between upfront and postneoadjuvant operations) and local unresectability in locally advanced disease. No preoperative variable was associated with uncompleted resection in upfront explorations, while anatomic staging informed the likelihood of surgical attrition following neoadjuvant treatment. Uncompleted resection was invariably associated with a median survival of around 1 year. The median postpancreatectomy survival was 36.9 months in the upfront setting and 29.5 months following neoadjuvant treatment. The median survival from diagnosis in patients receiving postneoadjuvant resection was 34.5 months. CONCLUSIONS: This analysis provided contemporary information about resection rates, reasons for intraoperative attrition, and survival outcomes in the entire spectrum of patients with PDAC selected for surgical exploration at an experienced institution.
引用
- Malleo G, Casciani F, Lionetto G, et al. Resection to Exploration Ratios and Associated Outcomes in Patients with Pancreatic Ductal Adenocarcinoma. Ann Surg. 2024. PMID: 38214158. doi:10.1097/SLA.0000000000006197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。